Open, randomised phase III study assessing the toxicity and efficacy of platinum-based chemotherapy with vitamin supplementation in the treatment of lung cancer
ISRCTN | ISRCTN87343655 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN87343655 |
Secondary identifying numbers | N/A |
- Submission date
- 11/11/2005
- Registration date
- 24/11/2005
- Last edited
- 03/03/2015
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Mary O'Brien
Scientific
Scientific
Royal Marsden Hospital
Downs Road
Sutton
SM2 5PT
United Kingdom
Study information
Study design | Open randomised phase III trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Open, randomised phase III study assessing the toxicity and efficacy of platinum-based chemotherapy with vitamin supplementation in the treatment of lung cancer |
Study acronym | MVPV1 |
Study objectives | To assess whether the addition of vitamin supplementation to chemotherapy may decrease treatment related toxicity and improve efficacy and outcome |
Ethics approval(s) | Approved by the Royal Marsden Hospital, 20/01/2006, ref: 05/Q0801/178 |
Health condition(s) or problem(s) studied | Lung cancer |
Intervention | Cisplatin-based chemotherapy +/- vitamin supplementation |
Intervention type | Mixed |
Primary outcome measure | 1. Incidence of neutropenia 2. Incidence of mucositis 3. Incidence of emesis |
Secondary outcome measures | 1. Disease response by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 2. Response rate 3. Overall survival |
Overall study start date | 01/01/2006 |
Completion date | 01/01/2008 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 84 |
Key inclusion criteria | 1. Written informed consent 2. Male or female, aged over 18 years 3. Histologically or cytologically confirmed Non-Small Cell Lung Cancer (NSCLC), SCLC or mesothelioma: locally advanced or metastatic; where giving cisplatin 75 mg/m^2 is appropriate 4. Eastern Cooperative Oncology Group (ECOG): performance status (PS) zero to two 5. Lab requirements at entry: serum creatinine less that or equal to 1.25 Upper Limit of Normal (ULN), creatinine clearance more than 50 ml/min (Ethylene Diamine Tetra-acetic Acid [EDTA]) or more than 60 ml/min (C+G), white blood cell count (WBC) more than 3 x 10^9/l, neutrophils more than 1.5 x 10^9/l, platelets more than 100 x 10^9/l 6. Presence of at least one bi-dimensionally measurable index lesion 7. Effective contraception if indicated 8. Estimated life expectancy of at least 12 weeks 9. Patients are required to stop all complimentary medicines and prior vitamin supplements |
Key exclusion criteria | 1. Pregnant or lactating women 2. Active infection 3. Inability or unwillingness to take vitamin supplementation 4. Serious systemic disorders incompatible with the study at the discretion of the investigator |
Date of first enrolment | 01/01/2006 |
Date of final enrolment | 01/01/2008 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Royal Marsden Hospital
Sutton
SM2 5PT
United Kingdom
SM2 5PT
United Kingdom
Sponsor information
Royal Marsden Hospital (UK)
Hospital/treatment centre
Hospital/treatment centre
Downs Road
Sutton
SM2 5PT
England
United Kingdom
Website | http://www.royalmarsden.org |
---|---|
https://ror.org/034vb5t35 |
Funders
Funder type
Government
Royal Marsden NHS Foundation Trust
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 11/12/2014 | Yes | No |